Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M-(N,N,N-trimethylammonio)-2,2,2-trifluoro-1,1-dihydroxyethylbenzene is a synthetic small molecule belonging to the class of quaternary ammonium compounds and substituted anilines. It is best known as a potent inhibitor of acetylcholinesterase (AChE), acting as a transition-state analog and exhibiting femtomolar inhibitory potency. This compound has been studied primarily in biochemical research settings for its ability to inhibit AChE with extremely high affinity but has not been developed or approved for therapeutic use[4][7]. Its primary mechanism involves binding to the active site of acetylcholinesterase and preventing the breakdown of acetylcholine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on m-(n,n,n-trimethylammonio)-2,2,2-trifluoro-1,1-dihydroxyethylbenzene.